PT - JOURNAL ARTICLE AU - Jorine E. Hartman AU - Karin Klooster AU - Nick H.T. ten Hacken AU - Dirk-Jan Slebos TI - Long-term follow up after bronchoscopic lung volume reduction coil treatment DP - 2014 Sep 01 TA - European Respiratory Journal PG - 1777 VI - 44 IP - Suppl 58 4099 - http://erj.ersjournals.com/content/44/Suppl_58/1777.short 4100 - http://erj.ersjournals.com/content/44/Suppl_58/1777.full SO - Eur Respir J2014 Sep 01; 44 AB - Background: Bronchoscopic lung volume reduction coil (LVRC) treatment has shown to be clinically effective in patients with severe emphysema in the short term, but long term safety and efficacy has not been evaluated. We evaluated the LVRC treatment up to 3 year follow up (FU).Methods: 38 patients with severe emphysema (median age 59 years, FEV1 27%pred) who previously participated in our pilot LVRC trials, were voluntarily invited for a yearly visit. Safety was evaluated by chest-Xray and recording of adverse events. Efficacy by pulmonary function testing, 6MWD and questionnaires.Results: 35 patients visited us after 1 year, 27 after 2 year and 22 after 3 year. We witnessed no coil migrations on the FU X-rays. At 1 year FU, all clinical outcomes were significantly improved compared to baseline. At 2 years FU, only RV%pred, mMRC and the SGRQ score were still significantly improved, with at 3 years FU only a significant improvement in mMRC score, with 40% of the patients reaching the 6MWD minimal important difference, and 59% for the SGRQ (table1).Conclusion: Follow-up of our very first pilot patients shows that LVRC treatment is safe in the long term, with especially no late pneumothoraces, coil migrations or unexpected adverse events. Clinical benefit declines over time with at 3 years still a significant number of patients responding for 6MWT, SGRQ and mMRC, not taking the expected disease related decline over time into account.